485 related articles for article (PubMed ID: 28077641)
1. Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain.
van den Pol AN; Mao G; Chattopadhyay A; Rose JK; Davis JN
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077641
[TBL] [Abstract][Full Text] [Related]
2. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.
Ryder AB; Buonocore L; Vogel L; Nachbagauer R; Krammer F; Rose JK
J Virol; 2015 Mar; 89(5):2820-30. PubMed ID: 25540378
[TBL] [Abstract][Full Text] [Related]
3. Chikungunya-vesicular stomatitis chimeric virus targets and eliminates brain tumors.
Zhang X; Mao G; van den Pol AN
Virology; 2018 Sep; 522():244-259. PubMed ID: 30055515
[TBL] [Abstract][Full Text] [Related]
4. A chimeric vesiculo/alphavirus is an effective alphavirus vaccine.
Chattopadhyay A; Wang E; Seymour R; Weaver SC; Rose JK
J Virol; 2013 Jan; 87(1):395-402. PubMed ID: 23077320
[TBL] [Abstract][Full Text] [Related]
5. Highly attenuated recombinant vesicular stomatitis virus VSV-12'GFP displays immunogenic and oncolytic activity.
van den Pol AN; Davis JN
J Virol; 2013 Jan; 87(2):1019-34. PubMed ID: 23135719
[TBL] [Abstract][Full Text] [Related]
6. Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.
Wollmann G; Drokhlyansky E; Davis JN; Cepko C; van den Pol AN
J Virol; 2015 Jul; 89(13):6711-24. PubMed ID: 25878115
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.
Ryder AB; Nachbagauer R; Buonocore L; Palese P; Krammer F; Rose JK
J Virol; 2015 Dec; 90(5):2544-50. PubMed ID: 26676789
[TBL] [Abstract][Full Text] [Related]
8. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.
Kahn JS; Roberts A; Weibel C; Buonocore L; Rose JK
J Virol; 2001 Nov; 75(22):11079-87. PubMed ID: 11602747
[TBL] [Abstract][Full Text] [Related]
9. Complementing defective viruses that express separate paramyxovirus glycoproteins provide a new vaccine vector approach.
Chattopadhyay A; Rose JK
J Virol; 2011 Mar; 85(5):2004-11. PubMed ID: 21177820
[TBL] [Abstract][Full Text] [Related]
10. Rhabdovirus-based vaccine platforms against henipaviruses.
Kurup D; Wirblich C; Feldmann H; Marzi A; Schnell MJ
J Virol; 2015 Jan; 89(1):144-54. PubMed ID: 25320306
[TBL] [Abstract][Full Text] [Related]
11. Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential.
Monath TP; Nichols R; Tussey L; Scappaticci K; Pullano TG; Whiteman MD; Vasilakis N; Rossi SL; Campos RK; Azar SR; Spratt HM; Seaton BL; Archambault WT; Costecalde YV; Moore EH; Hawks RJ; Fusco J
PLoS Pathog; 2022 Jun; 18(6):e1010658. PubMed ID: 35759511
[TBL] [Abstract][Full Text] [Related]
12. Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters.
Lo MK; Bird BH; Chattopadhyay A; Drew CP; Martin BE; Coleman JD; Rose JK; Nichol ST; Spiropoulou CF
Antiviral Res; 2014 Jan; 101():26-9. PubMed ID: 24184127
[TBL] [Abstract][Full Text] [Related]
13. A recombinant virus vaccine that protects against both Chikungunya and Zika virus infections.
Chattopadhyay A; Aguilar PV; Bopp NE; Yarovinsky TO; Weaver SC; Rose JK
Vaccine; 2018 Jun; 36(27):3894-3900. PubMed ID: 29807712
[TBL] [Abstract][Full Text] [Related]
14. Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.
Reynolds TD; Buonocore L; Rose NF; Rose JK; Robek MD
J Virol; 2015 Oct; 89(20):10407-15. PubMed ID: 26246574
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a Bivalent Vaccine Capable of Inducing Protection Against Both Ebola and Cross-clade H5N1 Influenza in Mice.
Wong G; Qiu X; Ebihara H; Feldmann H; Kobinger GP
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S435-42. PubMed ID: 26022441
[TBL] [Abstract][Full Text] [Related]
16. Peripheral immunization blocks lethal actions of vesicular stomatitis virus within the brain.
Ozduman K; Wollmann G; Ahmadi SA; van den Pol AN
J Virol; 2009 Nov; 83(22):11540-9. PubMed ID: 19726512
[TBL] [Abstract][Full Text] [Related]
17. Recoding of the vesicular stomatitis virus L gene by computer-aided design provides a live, attenuated vaccine candidate.
Wang B; Yang C; Tekes G; Mueller S; Paul A; Whelan SP; Wimmer E
mBio; 2015 Mar; 6(2):. PubMed ID: 25827413
[TBL] [Abstract][Full Text] [Related]
18. Mucin-Like Domain of Ebola Virus Glycoprotein Enhances Selective Oncolytic Actions against Brain Tumors.
Zhang X; Zhang T; Davis JN; Marzi A; Marchese AM; Robek MD; van den Pol AN
J Virol; 2020 Mar; 94(8):. PubMed ID: 32051271
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of propagation-restricted vesicular stomatitis virus encoding Ebola virus glycoprotein in guinea pigs.
Locher S; Schweneker M; Hausmann J; Zimmer G
J Gen Virol; 2018 Jul; 99(7):866-879. PubMed ID: 29869979
[TBL] [Abstract][Full Text] [Related]
20. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates.
Mire CE; Miller AD; Carville A; Westmoreland SV; Geisbert JB; Mansfield KG; Feldmann H; Hensley LE; Geisbert TW
PLoS Negl Trop Dis; 2012; 6(3):e1567. PubMed ID: 22448291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
